Frederick Frank (businessman)

Frederick Frank
Born(1932-05-31)May 31, 1932
DiedSeptember 11, 2021(2021-09-11) (aged 89)
Alma materYale University, Stanford Graduate School of Business
SpouseMary C. Tanner[1][2][3]
AwardsRichard J. Bolte Sr. Award
Scientific career
FieldsInvestment banking, biotechnology
InstitutionsEVOLUTION Life Science Partners, Peter J. Solomon Company, Lehman Brothers, Barclays Capital
External videos
video icon “BIO at 25-Jim Greenwood and Frederick Frank Discuss Early Biotech investment”, Biotechnology Innovation Organization, 2018

Frederick Frank (May 31, 1932 – September 11, 2021) was an American banker, with more than 50 years of experience on Wall Street. He is considered the first investment banker to have specialized in the areas of biotechnology, pharmaceuticals, and health care services.[4][5]

As of 2014, Frank became a founder and chair of EVOLUTION Life Science Partners. He previously served as vice chairman of Lehman Brothers, Barclays Capital, and the Peter J. Solomon Company.[4] He is credited as lead underwriter for over 125 IPOs and as a negotiator in over 75 mergers and acquisitions.[6] Frank was chosen as one of the top 100 contributors to biotechnology in 2005.[5][7]

  1. ^ "Advisory Council : Mary Tanner". LifeSciNYC. Retrieved May 14, 2019.
  2. ^ Abkowitz, Alyssa (March 20, 2009). "Health care's dealmaking couple is back Frank and Tanner, the first family of pharma finance, are together again in time for the industry's wave of consolidation". Fortune. Retrieved May 14, 2019.
  3. ^ "Mary C. Tanner Becomes a Bride". The New York Times. October 16, 1988. Retrieved May 14, 2019.
  4. ^ a b Cite error: The named reference Institute was invoked but never defined (see the help page).
  5. ^ a b "The top 100 living contributors to biotechnology" (PDF). Reed Elsevier. 2005. Retrieved May 14, 2019.
  6. ^ Cite error: The named reference Greenwood was invoked but never defined (see the help page).
  7. ^ "The Top 100 Living Contributors to Biotechnology". AgBioWorld. 2005. Retrieved May 14, 2019.